Does the media refer more to SMTI or NNOX?

In the previous week, Nano-X Imaging had 10 more articles in the media than Sanara MedTech. MarketBeat recorded 22 mentions for Nano-X Imaging and 12 mentions for Sanara MedTech. Nano-X Imaging's average media sentiment score of 0.21 beat Sanara MedTech's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nano-X Imaging 4 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NNOX or FOCL more profitable?

FocalTherics has a net margin of -41.47% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets Nano-X Imaging -716.44% -70.96% -62.26% FocalTherics -41.47% -137.61% -40.62%

Does the media favor NNOX or FOCL?

In the previous week, Nano-X Imaging had 18 more articles in the media than FocalTherics. MarketBeat recorded 22 mentions for Nano-X Imaging and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat Nano-X Imaging's score of 0.21 indicating that FocalTherics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nano-X Imaging 4 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral FocalTherics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NNOX or OBIO?

In the previous week, Nano-X Imaging had 21 more articles in the media than Orchestra BioMed. MarketBeat recorded 22 mentions for Nano-X Imaging and 1 mentions for Orchestra BioMed. Nano-X Imaging's average media sentiment score of 0.21 beat Orchestra BioMed's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nano-X Imaging 4 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Orchestra BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, NNOX or RXST?

RxSight has higher revenue and earnings than Nano-X Imaging. RxSight is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nano-X Imaging $14.52M 4.70 -$75.02M -$1.58 N/A RxSight $134.48M 1.85 -$38.94M -$1.13 N/A

Is NNOX or RXST more profitable?

RxSight has a net margin of -36.58% compared to Nano-X Imaging's net margin of -716.44%. RxSight's return on equity of -17.01% beat Nano-X Imaging's return on equity. Company Net Margins Return on Equity Return on Assets Nano-X Imaging -716.44% -70.96% -62.26% RxSight -36.58% -17.01% -15.12%

Does the media favor NNOX or RXST?

In the previous week, Nano-X Imaging had 18 more articles in the media than RxSight. MarketBeat recorded 22 mentions for Nano-X Imaging and 4 mentions for RxSight. RxSight's average media sentiment score of 0.41 beat Nano-X Imaging's score of 0.21 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nano-X Imaging 4 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NNOX or CNXU?

In the previous week, Nano-X Imaging had 14 more articles in the media than Conexeu Sciences. MarketBeat recorded 22 mentions for Nano-X Imaging and 8 mentions for Conexeu Sciences. Nano-X Imaging's average media sentiment score of 0.21 beat Conexeu Sciences' score of 0.12 indicating that Nano-X Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nano-X Imaging 4 Very Positive mention(s) 1 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Nano-X Imaging (NNOX) Competitors

$0.98 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.96 -0.02 (-2.54%)

As of 07/31/2026 07:35 PM Eastern

Compare

NNOX vs. SMTI, FOCL, OBIO, RXST, and CNXU

Should you buy Nano-X Imaging stock or one of its competitors? MarketBeat compares Nano-X Imaging with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nano-X Imaging include Sanara MedTech (SMTI), FocalTherics (FOCL), Orchestra BioMed (OBIO), RxSight (RXST), and Conexeu Sciences (CNXU).

How does Nano-X Imaging compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Sanara MedTech has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 7.7% of Nano-X Imaging shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sanara MedTech has a net margin of -31.23% compared to Nano-X Imaging's net margin of -716.44%. Sanara MedTech's return on equity of -3.19% beat Nano-X Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Nano-X Imaging	-716.44%	-70.96%	-62.26%

In the previous week, Nano-X Imaging had 10 more articles in the media than Sanara MedTech. MarketBeat recorded 22 mentions for Nano-X Imaging and 12 mentions for Sanara MedTech. Nano-X Imaging's average media sentiment score of 0.21 beat Sanara MedTech's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nano-X Imaging	4 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanara MedTech presently has a consensus price target of $35.00, suggesting a potential upside of 3.37%. Nano-X Imaging has a consensus price target of $4.00, suggesting a potential upside of 308.20%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.20
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67

Sanara MedTech has higher revenue and earnings than Nano-X Imaging. Sanara MedTech is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$107.48M	2.89	-$37.56M	-$3.77	N/A
Nano-X Imaging	$14.52M	4.70	-$75.02M	-$1.58	N/A

Summary

Nano-X Imaging beats Sanara MedTech on 11 of the 17 factors compared between the two stocks.

How does Nano-X Imaging compare to FocalTherics?

Nano-X Imaging (NASDAQ:NNOX) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Nano-X Imaging has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Nano-X Imaging currently has a consensus price target of $4.00, suggesting a potential upside of 308.20%. FocalTherics has a consensus price target of $9.00, suggesting a potential upside of 47.06%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Nano-X Imaging is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

FocalTherics has higher revenue and earnings than Nano-X Imaging. FocalTherics is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$14.52M	4.70	-$75.02M	-$1.58	N/A
FocalTherics	$70.53M	3.25	-$29.25M	-$0.81	N/A

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 62.7% of FocalTherics shares are held by institutional investors. 7.7% of Nano-X Imaging shares are held by company insiders. Comparatively, 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Nano-X Imaging had 18 more articles in the media than FocalTherics. MarketBeat recorded 22 mentions for Nano-X Imaging and 4 mentions for FocalTherics. FocalTherics' average media sentiment score of 0.65 beat Nano-X Imaging's score of 0.21 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nano-X Imaging	4 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
FocalTherics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FocalTherics has a net margin of -41.47% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-716.44%	-70.96%	-62.26%
FocalTherics	-41.47%	-137.61%	-40.62%

Summary

Nano-X Imaging and FocalTherics tied by winning 8 of the 16 factors compared between the two stocks.

How does Nano-X Imaging compare to Orchestra BioMed?

Nano-X Imaging (NASDAQ:NNOX) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Nano-X Imaging currently has a consensus target price of $4.00, indicating a potential upside of 308.20%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 241.71%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nano-X Imaging is more favorable than Orchestra BioMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Orchestra BioMed has higher revenue and earnings than Nano-X Imaging. Orchestra BioMed is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$14.52M	4.70	-$75.02M	-$1.58	N/A
Orchestra BioMed	$32.72M	7.28	-$52.70M	-$0.97	N/A

Nano-X Imaging has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

In the previous week, Nano-X Imaging had 21 more articles in the media than Orchestra BioMed. MarketBeat recorded 22 mentions for Nano-X Imaging and 1 mentions for Orchestra BioMed. Nano-X Imaging's average media sentiment score of 0.21 beat Orchestra BioMed's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nano-X Imaging	4 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a net margin of -166.96% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-716.44%	-70.96%	-62.26%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nano-X Imaging beats Orchestra BioMed on 9 of the 17 factors compared between the two stocks.

How does Nano-X Imaging compare to RxSight?

Nano-X Imaging (NASDAQ:NNOX) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

RxSight has a net margin of -36.58% compared to Nano-X Imaging's net margin of -716.44%. RxSight's return on equity of -17.01% beat Nano-X Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-716.44%	-70.96%	-62.26%
RxSight	-36.58%	-17.01%	-15.12%

RxSight has higher revenue and earnings than Nano-X Imaging. RxSight is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$14.52M	4.70	-$75.02M	-$1.58	N/A
RxSight	$134.48M	1.85	-$38.94M	-$1.13	N/A

Nano-X Imaging has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, RxSight has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 7.7% of Nano-X Imaging shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nano-X Imaging currently has a consensus price target of $4.00, suggesting a potential upside of 308.20%. RxSight has a consensus price target of $8.50, suggesting a potential upside of 41.43%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Nano-X Imaging is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, Nano-X Imaging had 18 more articles in the media than RxSight. MarketBeat recorded 22 mentions for Nano-X Imaging and 4 mentions for RxSight. RxSight's average media sentiment score of 0.41 beat Nano-X Imaging's score of 0.21 indicating that RxSight is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nano-X Imaging	4 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats Nano-X Imaging on 10 of the 17 factors compared between the two stocks.

How does Nano-X Imaging compare to Conexeu Sciences?

Nano-X Imaging (NASDAQ:NNOX) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Conexeu Sciences has lower revenue, but higher earnings than Nano-X Imaging. Conexeu Sciences is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$14.52M	4.70	-$75.02M	-$1.58	N/A
Conexeu Sciences	N/A	N/A	N/A	-$0.11	N/A

In the previous week, Nano-X Imaging had 14 more articles in the media than Conexeu Sciences. MarketBeat recorded 22 mentions for Nano-X Imaging and 8 mentions for Conexeu Sciences. Nano-X Imaging's average media sentiment score of 0.21 beat Conexeu Sciences' score of 0.12 indicating that Nano-X Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nano-X Imaging	4 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nano-X Imaging currently has a consensus price target of $4.00, indicating a potential upside of 308.20%. Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 140.67%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, equities analysts clearly believe Nano-X Imaging is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.67
Conexeu Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Conexeu Sciences has a net margin of 0.00% compared to Nano-X Imaging's net margin of -716.44%. Conexeu Sciences' return on equity of 0.00% beat Nano-X Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-716.44%	-70.96%	-62.26%
Conexeu Sciences	N/A	N/A	N/A

21.5% of Nano-X Imaging shares are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Nano-X Imaging beats Conexeu Sciences on 9 of the 13 factors compared between the two stocks.

Get Nano-X Imaging News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNOX vs. The Competition

Export

Metric	Nano-X Imaging	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$68.20M	$5.58B	$6.85B	$12.42B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	-0.62	23.11	282.30	24.66
Price / Sales	4.70	56.82	564.25	75.48
Price / Cash	N/A	32.53	28.60	46.71
Price / Book	0.49	6.29	10.98	6.07
Net Income	-$75.02M	$151.15M	$3.49B	$347.99M
7 Day Performance	10.60%	1.02%	-0.60%	-0.44%
1 Month Performance	-24.62%	-3.44%	-5.19%	-4.81%
1 Year Performance	-78.70%	2.34%	62.02%	18.61%

Nano-X Imaging Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNOX Nano-X Imaging	3.7454 of 5 stars	$0.98 flat	$4.00 +308.2%	-78.7%	$68.20M	$14.52M	N/A	190
SMTI Sanara MedTech	0.8408 of 5 stars	$25.85 +1.1%	$34.00 +31.5%	+40.1%	$234.23M	$103.12M	N/A	60	Analyst Downgrade
FOCL FocalTherics	3.4682 of 5 stars	$6.15 +2.0%	$9.00 +46.3%	N/A	$226.02M	$70.53M	N/A	230	Analyst Upgrade
OBIO Orchestra BioMed	3.2273 of 5 stars	$3.82 +2.1%	$13.60 +256.0%	+63.1%	$223.95M	$33.48M	N/A	4
RXST RxSight	3.6242 of 5 stars	$5.64 +8.7%	$8.89 +57.6%	-22.9%	$214.85M	$134.48M	N/A	220	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNOX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nano-X Imaging (NNOX) Competitors

NNOX vs. SMTI, FOCL, OBIO, RXST, and CNXU

How does Nano-X Imaging compare to Sanara MedTech?

Summary

How does Nano-X Imaging compare to FocalTherics?

Summary

How does Nano-X Imaging compare to Orchestra BioMed?

Summary

How does Nano-X Imaging compare to RxSight?

Summary

How does Nano-X Imaging compare to Conexeu Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNOX vs. The Competition

Nano-X Imaging Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nano-X Imaging (NNOX) Competitors

NNOX vs. SMTI, FOCL, OBIO, RXST, and CNXU

How does Nano-X Imaging compare to Sanara MedTech?

Which has more risk and volatility, SMTI or NNOX?

Do institutionals & insiders hold more shares of SMTI or NNOX?

Is SMTI or NNOX more profitable?

Does the media refer more to SMTI or NNOX?

Do analysts recommend SMTI or NNOX?

Which has stronger valuation and earnings, SMTI or NNOX?

Summary

How does Nano-X Imaging compare to FocalTherics?

Which has more risk & volatility, NNOX or FOCL?

Do analysts rate NNOX or FOCL?

Which has stronger valuation & earnings, NNOX or FOCL?

Do institutionals and insiders hold more shares of NNOX or FOCL?

Does the media favor NNOX or FOCL?

Is NNOX or FOCL more profitable?

Summary

How does Nano-X Imaging compare to Orchestra BioMed?

Do analysts rate NNOX or OBIO?

Which has better valuation and earnings, NNOX or OBIO?

Which has more risk & volatility, NNOX or OBIO?

Does the media favor NNOX or OBIO?

Is NNOX or OBIO more profitable?

Do institutionals & insiders believe in NNOX or OBIO?

Summary

How does Nano-X Imaging compare to RxSight?

Is NNOX or RXST more profitable?

Which has higher valuation & earnings, NNOX or RXST?

Which has more volatility & risk, NNOX or RXST?

Do institutionals & insiders have more ownership in NNOX or RXST?

Do analysts prefer NNOX or RXST?

Does the media favor NNOX or RXST?

Summary

How does Nano-X Imaging compare to Conexeu Sciences?

Which has stronger valuation & earnings, NNOX or CNXU?

Does the media refer more to NNOX or CNXU?

Do analysts prefer NNOX or CNXU?

Is NNOX or CNXU more profitable?

Do insiders and institutionals believe in NNOX or CNXU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNOX vs. The Competition

Nano-X Imaging Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools